Alzheimer’s disease could affect more than 14 million Americans by 2050 if a cure isn’t found, the Alzheimer’s Association reports. The Center for Alzheimer’s Disease and Related Disorders, part of SIU Medicine’s Neuroscience Institute, is hoping new research studies might change that.

 

Three clinical trials, including the Aware Study by AbbVie, Tauriel Study by Genentech, and GRADUATE I Study by Roche, are now recruiting participants with memory impairment or probable mild-to-moderate Alzheimer’s disease. The goal of these studies is test how well the medical treatments work at slowing the progression of the disease and whether they are safe. All study-related drugs and assessments will be provided at no cost to the participant. Participants may also receive a stipend to cover travel, meals and other related expenses.

 

To qualify, participants must:

 

• Be between 50-90 years of age

• Have symptoms consistent with mild cognitive impairment or probable Alzheimer’s disease

• Be willing to undergo position emission tomography (PET) scans and magnetic resonance imaging (MRI)

• Have a reliable study partner or caregiver who is willing to participate, attend study visits and answer questions about the participant’s health

 

To learn more about these studies and qualifications, call Barbara Lokaitis at 217-545-9737.